{"transactions":[{"id":682666,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":22021,"kind":"person","name":"Fisher Michal","position":1,"cik":"0002139619","reported_name":"Fisher Michal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-18T13:01:03.000Z","date":"2026-05-18","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":5,"value":10000.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001683168-26-006553","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316826006553/ownership.xml","form_type":"4"}},{"id":682665,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":22020,"kind":"person","name":"Levin Rami","position":1,"cik":"0002102719","reported_name":"Levin Rami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T13:00:03.000Z","date":"2026-08-14","kind":"exercise","planned":false,"acquired":false,"shares":4750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 1, 2026, the reporting person was granted 19,000 restricted stock units, vesting as follows: 25% on the six-month anniversary of the grant date, 25% on the twelve-month anniversary of the grant date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 1, 2026, the reporting person was granted 19,000 restricted stock units, vesting as follows: 25% on the six-month anniversary of the grant date, 25% on the twelve-month anniversary of the grant date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 1, 2026, the reporting person was granted 19,000 restricted stock units, vesting as follows: 25% on the six-month anniversary of the grant date, 25% on the twelve-month anniversary of the grant date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date."}],"balance_after":14250,"derivative":{"underlying":"Common Stock","underlying_shares":4750},"source":{"system":"sec-edgar","filing":"0001683168-26-006552","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316826006552/ownership.xml","form_type":"4"}},{"id":682664,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":22020,"kind":"person","name":"Levin Rami","position":1,"cik":"0002102719","reported_name":"Levin Rami","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-08-18T13:00:03.000Z","date":"2026-08-14","kind":"exercise","planned":false,"acquired":false,"shares":4750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4750,"source":{"system":"sec-edgar","filing":"0001683168-26-006552","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316826006552/ownership.xml","form_type":"4"}},{"id":770170,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":45701,"kind":"person","name":"Charles Faith L.","position":1,"cik":"0001853985","reported_name":"Charles Faith L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T09:03:22.000Z","date":"2026-05-18","kind":"purchase","planned":false,"acquired":true,"shares":7100,"price":4.789,"value":34001.9,"ownership":{"direct":true},"balance_after":7100,"source":{"system":"sec-edgar","filing":"0001683168-26-004145","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853985/000168316826004145/ownership.xml","form_type":"4"}},{"id":860542,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":62749,"kind":"person","name":"Faulkner Eric","position":1,"cik":"0002113815","reported_name":"Faulkner Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T22:02:29.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":9500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date."}],"balance_after":9500,"derivative":{"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001683168-26-001491","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316826001491/ownership.xml","form_type":"4"}},{"id":860670,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T17:01:43.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":9500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date."}],"balance_after":9500,"derivative":{"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001683168-26-001489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1615840/000168316826001489/ownership.xml","form_type":"4"}},{"id":954859,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":22020,"kind":"person","name":"Levin Rami","position":1,"cik":"0002102719","reported_name":"Levin Rami","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-01-02T22:01:02.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":19000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date."}],"balance_after":19000,"derivative":{"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001683168-26-000016","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316826000016/ownership.xml","form_type":"4"}},{"id":993521,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":35682,"kind":"person","name":"Keyes Jeffry R.","position":1,"cik":"0001557736","reported_name":"Keyes Jeffry R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2025-11-20T02:07:48.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":1517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the \"Shareholder Approval Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date."}],"balance_after":1517,"derivative":{"exercise_price":12.48,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":1517},"source":{"system":"sec-edgar","filing":"0001683168-25-008576","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557736/000168316825008576/ownership.xml","form_type":"4"}},{"id":993440,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":38058,"kind":"person","name":"Cockroft Bettina M.","position":1,"cik":"0001900452","reported_name":"Cockroft Bettina M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2025-11-19T22:00:09.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":1517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the \"Shareholder Approval Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date."}],"balance_after":1517,"derivative":{"exercise_price":12.48,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":1517},"source":{"system":"sec-edgar","filing":"0001683168-25-008566","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316825008566/ownership.xml","form_type":"4"}},{"id":993863,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase common stock","published_at":"2025-11-19T22:00:02.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":4881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the \"Grant Date\"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date."}],"balance_after":4881,"derivative":{"exercise_price":30,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":4881},"source":{"system":"sec-edgar","filing":"0001683168-25-008562","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316825008562/ownership.xml","form_type":"4"}},{"id":993428,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72876,"kind":"person","name":"Gumulka Jerzy","position":1,"cik":"0001793252","reported_name":"Gumulka Jerzy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2025-11-19T22:00:02.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":1517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the \"Shareholder Approval Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date."}],"balance_after":1517,"derivative":{"exercise_price":12.48,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":1517},"source":{"system":"sec-edgar","filing":"0001683168-25-008561","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316825008561/ownership.xml","form_type":"4"}},{"id":993805,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase common stock","published_at":"2025-11-19T17:00:07.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":9761,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the \"Grant Date\"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date."}],"balance_after":9761,"derivative":{"exercise_price":30,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":9761},"source":{"system":"sec-edgar","filing":"0001683168-25-008564","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316825008564/ownership.xml","form_type":"4"}},{"id":994138,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72894,"kind":"person","name":"Mahery Amy","position":1,"cik":"0002008489","reported_name":"Mahery Amy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2025-11-19T17:00:06.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":1517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the \"Shareholder Approval Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date."}],"balance_after":1517,"derivative":{"exercise_price":12.48,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":1517},"source":{"system":"sec-edgar","filing":"0001683168-25-008565","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008489/000168316825008565/ownership.xml","form_type":"4"}},{"id":993980,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":45701,"kind":"person","name":"Charles Faith L.","position":1,"cik":"0001853985","reported_name":"Charles Faith L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2025-11-19T17:00:04.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":1517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the \"Shareholder Approval Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date."}],"balance_after":1517,"derivative":{"exercise_price":12.48,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":1517},"source":{"system":"sec-edgar","filing":"0001683168-25-008563","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853985/000168316825008563/ownership.xml","form_type":"4"}},{"id":1543602,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":35682,"kind":"person","name":"Keyes Jeffry R.","position":1,"cik":"0001557736","reported_name":"Keyes Jeffry R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-04-11T01:52:52.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The awards were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":80428,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001683168-24-002289","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557736/000168316824002289/ownership.xml","form_type":"4"}},{"id":1543601,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":35682,"kind":"person","name":"Keyes Jeffry R.","position":1,"cik":"0001557736","reported_name":"Keyes Jeffry R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2024-04-11T01:52:52.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The awards were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":62928,"derivative":{"exercise_price":0.2586,"expiration_date":"2034-04-08","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001683168-24-002289","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557736/000168316824002289/ownership.xml","form_type":"4"}},{"id":1543567,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72876,"kind":"person","name":"Gumulka Jerzy","position":1,"cik":"0001793252","reported_name":"Gumulka Jerzy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-04-11T01:52:22.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The awards were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":147594,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001683168-24-002288","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824002288/ownership.xml","form_type":"4"}},{"id":1543566,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72876,"kind":"person","name":"Gumulka Jerzy","position":1,"cik":"0001793252","reported_name":"Gumulka Jerzy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2024-04-11T01:52:22.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The awards were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":129594,"derivative":{"exercise_price":0.2586,"expiration_date":"2034-04-08","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001683168-24-002288","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824002288/ownership.xml","form_type":"4"}},{"id":1543563,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":92076,"kind":"person","name":"Evans Carl Anthony","position":1,"cik":"0001792582","reported_name":"Evans Carl Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-04-11T01:52:02.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The awards were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":147094,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001683168-24-002287","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824002287/ownership.xml","form_type":"4"}},{"id":1543562,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":92076,"kind":"person","name":"Evans Carl Anthony","position":1,"cik":"0001792582","reported_name":"Evans Carl Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2024-04-11T01:52:02.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The awards were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":129594,"derivative":{"exercise_price":0.2586,"expiration_date":"2034-04-08","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001683168-24-002287","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824002287/ownership.xml","form_type":"4"}},{"id":1543820,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-11T01:51:35.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units set forth in the table vest in eight equal quarterly installments over two years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units set forth in the table vest in eight equal quarterly installments over two years."}],"balance_after":241.572,"derivative":{"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001683168-24-002286","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316824002286/ownership.xml","form_type":"4"}},{"id":1543819,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase common stock","published_at":"2024-04-11T01:51:35.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options set forth in the table vest in 36 equal monthly installments over three years."}],"balance_after":201.572,"derivative":{"exercise_price":0.2586,"expiration_date":"2034-04-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001683168-24-002286","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316824002286/ownership.xml","form_type":"4"}},{"id":1543565,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":38058,"kind":"person","name":"Cockroft Bettina M.","position":1,"cik":"0001900452","reported_name":"Cockroft Bettina M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-04-11T01:51:15.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The awards were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":53074,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001683168-24-002285","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824002285/ownership.xml","form_type":"4"}},{"id":1543564,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":38058,"kind":"person","name":"Cockroft Bettina M.","position":1,"cik":"0001900452","reported_name":"Cockroft Bettina M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2024-04-11T01:51:15.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The awards were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":35574,"derivative":{"exercise_price":0.2586,"expiration_date":"2034-04-08","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001683168-24-002285","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824002285/ownership.xml","form_type":"4"}},{"id":1543923,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72894,"kind":"person","name":"Mahery Amy","position":1,"cik":"0002008489","reported_name":"Mahery Amy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-04-10T21:53:15.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The awards were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":47420,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001683168-24-002290","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2008489/000168316824002290/ownership.xml","form_type":"4"}},{"id":1543922,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72894,"kind":"person","name":"Mahery Amy","position":1,"cik":"0002008489","reported_name":"Mahery Amy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2024-04-10T21:53:15.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The awards were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":29920,"derivative":{"exercise_price":0.2586,"expiration_date":"2034-04-08","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001683168-24-002290","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008489/000168316824002290/ownership.xml","form_type":"4"}},{"id":1543745,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-10T21:50:50.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":83000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units set forth in the table vest in eight equal quarterly installments over two years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units set forth in the table vest in eight equal quarterly installments over two years."}],"balance_after":559533,"derivative":{"underlying":"Common Stock","underlying_shares":83000},"source":{"system":"sec-edgar","filing":"0001683168-24-002284","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316824002284/ownership.xml","form_type":"4"}},{"id":1543744,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase common stock","published_at":"2024-04-10T21:50:50.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":83000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options set forth in the table vest in 36 equal monthly installments over three years."}],"balance_after":476533,"derivative":{"exercise_price":0.2586,"expiration_date":"2034-04-08","underlying":"Common Stock","underlying_shares":83000},"source":{"system":"sec-edgar","filing":"0001683168-24-002284","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316824002284/ownership.xml","form_type":"4"}},{"id":1543892,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":45701,"kind":"person","name":"Charles Faith L.","position":1,"cik":"0001853985","reported_name":"Charles Faith L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-04-10T21:50:26.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The awards were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":64815,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001683168-24-002283","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853985/000168316824002283/ownership.xml","form_type":"4"}},{"id":1543891,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":45701,"kind":"person","name":"Charles Faith L.","position":1,"cik":"0001853985","reported_name":"Charles Faith L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2024-04-10T21:50:26.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The awards were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":47315,"derivative":{"exercise_price":0.2586,"expiration_date":"2034-04-08","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001683168-24-002283","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853985/000168316824002283/ownership.xml","form_type":"4"}},{"id":1656411,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72876,"kind":"person","name":"Gumulka Jerzy","position":1,"cik":"0001793252","reported_name":"Gumulka Jerzy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrant to purchase common stock","published_at":"2024-02-06T15:28:10.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":33333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":112094,"derivative":{"exercise_price":0.3,"exercise_date":"2024-02-01","expiration_date":"2025-10-01","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0001683168-24-000708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824000708/ownership.xml","form_type":"4"}},{"id":1656410,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72876,"kind":"person","name":"Gumulka Jerzy","position":1,"cik":"0001793252","reported_name":"Gumulka Jerzy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrant to purchase common stock","published_at":"2024-02-06T15:28:10.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":33333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":78761,"derivative":{"exercise_price":0.3,"exercise_date":"2024-02-01","expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0001683168-24-000708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824000708/ownership.xml","form_type":"4"}},{"id":1656409,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72876,"kind":"person","name":"Gumulka Jerzy","position":1,"cik":"0001793252","reported_name":"Gumulka Jerzy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-02-06T15:28:10.000Z","date":"2024-02-01","kind":"purchase","planned":false,"acquired":true,"shares":33333,"price":0.3,"value":9999.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":43006,"source":{"system":"sec-edgar","filing":"0001683168-24-000708","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824000708/ownership.xml","form_type":"4"}},{"id":1656408,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":92076,"kind":"person","name":"Evans Carl Anthony","position":1,"cik":"0001792582","reported_name":"Evans Carl Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrant to purchase common stock","published_at":"2024-02-06T15:27:56.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":33333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":112094,"derivative":{"exercise_price":0.3,"exercise_date":"2024-02-01","expiration_date":"2025-10-01","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0001683168-24-000707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824000707/ownership.xml","form_type":"4"}},{"id":1656407,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":92076,"kind":"person","name":"Evans Carl Anthony","position":1,"cik":"0001792582","reported_name":"Evans Carl Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrant to purchase common stock","published_at":"2024-02-06T15:27:56.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":33333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":78761,"derivative":{"exercise_price":0.3,"exercise_date":"2024-02-01","expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0001683168-24-000707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824000707/ownership.xml","form_type":"4"}},{"id":1656406,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":92076,"kind":"person","name":"Evans Carl Anthony","position":1,"cik":"0001792582","reported_name":"Evans Carl Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-02-06T15:27:56.000Z","date":"2024-02-01","kind":"purchase","planned":false,"acquired":true,"shares":33333,"price":0.3,"value":9999.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":33458,"source":{"system":"sec-edgar","filing":"0001683168-24-000707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824000707/ownership.xml","form_type":"4"}},{"id":1656809,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series B Warrant to purchase common stock","published_at":"2024-02-06T15:27:39.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":161572,"derivative":{"exercise_price":0.3,"exercise_date":"2024-02-01","expiration_date":"2025-10-01","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001683168-24-000706","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316824000706/ownership.xml","form_type":"4"}},{"id":1656808,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Warrant to purchase common stock","published_at":"2024-02-06T15:27:39.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":94906,"derivative":{"exercise_price":0.3,"exercise_date":"2024-02-01","expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001683168-24-000706","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316824000706/ownership.xml","form_type":"4"}},{"id":1656807,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2024-02-06T15:27:39.000Z","date":"2024-02-01","kind":"purchase","planned":false,"acquired":true,"shares":66666,"price":0.3,"value":19999.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":103438,"source":{"system":"sec-edgar","filing":"0001683168-24-000706","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316824000706/ownership.xml","form_type":"4"}},{"id":1657115,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72894,"kind":"person","name":"Mahery Amy","position":1,"cik":"0002008489","reported_name":"Mahery Amy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2024-02-06T10:28:23.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":12420,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options set forth in this table vest in 36 equal monthly installments succeeding the issuance date, or February 1, 2024, subject to the grantee's continued service on the Company's Board of Directors on each vesting date."}],"balance_after":12420,"derivative":{"exercise_price":0.2525,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":12420},"source":{"system":"sec-edgar","filing":"0001683168-24-000709","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008489/000168316824000709/ownership.xml","form_type":"4"}},{"id":1656772,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B Warrant to purchase common stock","published_at":"2024-02-06T10:27:23.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":166666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":393533,"derivative":{"exercise_price":0.3,"exercise_date":"2024-02-01","expiration_date":"2025-10-01","underlying":"Common Stock","underlying_shares":166666},"source":{"system":"sec-edgar","filing":"0001683168-24-000705","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316824000705/ownership.xml","form_type":"4"}},{"id":1656771,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Warrant to purchase common stock","published_at":"2024-02-06T10:27:23.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":166666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":226867,"derivative":{"exercise_price":0.3,"exercise_date":"2024-02-01","expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":166666},"source":{"system":"sec-edgar","filing":"0001683168-24-000705","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316824000705/ownership.xml","form_type":"4"}},{"id":1656770,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-02-06T10:27:23.000Z","date":"2024-02-01","kind":"purchase","planned":false,"acquired":true,"shares":166666,"price":0.3,"value":49999.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024."}],"balance_after":215676,"source":{"system":"sec-edgar","filing":"0001683168-24-000705","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316824000705/ownership.xml","form_type":"4"}},{"id":1760962,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72876,"kind":"person","name":"Gumulka Jerzy","position":1,"cik":"0001793252","reported_name":"Gumulka Jerzy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-10-12T22:01:19.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":39475,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":45428,"derivative":{"exercise_price":1.09,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":39475},"source":{"system":"sec-edgar","filing":"0001683168-23-007111","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823007111/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-25"}},{"id":1760961,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":92076,"kind":"person","name":"Evans Carl Anthony","position":1,"cik":"0001792582","reported_name":"Evans Carl Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-10-12T22:01:15.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":39475,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":45428,"derivative":{"exercise_price":1.09,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":39475},"source":{"system":"sec-edgar","filing":"0001683168-23-007110","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823007110/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-25"}},{"id":1760999,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":35682,"kind":"person","name":"Keyes Jeffry R.","position":1,"cik":"0001557736","reported_name":"Keyes Jeffry R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-10-12T22:01:12.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":39475,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":45428,"derivative":{"exercise_price":1.09,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":39475},"source":{"system":"sec-edgar","filing":"0001683168-23-007109","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557736/000168316823007109/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-25"}},{"id":1760960,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":38058,"kind":"person","name":"Cockroft Bettina M.","position":1,"cik":"0001900452","reported_name":"Cockroft Bettina M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-10-12T22:00:10.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":9475,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":18074,"derivative":{"exercise_price":1.09,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":9475},"source":{"system":"sec-edgar","filing":"0001683168-23-007108","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823007108/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-25"}},{"id":1760959,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":38058,"kind":"person","name":"Cockroft Bettina M.","position":1,"cik":"0001900452","reported_name":"Cockroft Bettina M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-10-12T22:00:10.000Z","date":"2023-09-14","kind":"grant","planned":false,"acquired":true,"shares":6500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest in 36 equal monthly installments. The stock option was approved by the compensation committee of the company's board of directors on August 4, 2023, subject to shareholder approval of the 2020 Stock Plan under which the option was granted. The shareholders of the company approved the plan at the company's annual meeting on September 14, 2023."}],"balance_after":8599,"derivative":{"exercise_price":2.27,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001683168-23-007108","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823007108/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-25"}},{"id":1760958,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":109030,"kind":"person","name":"Andraczke Andrzej","position":1,"cik":"0001792732","reported_name":"Andraczke Andrzej","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-10-12T22:00:06.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":39475,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":45428,"derivative":{"exercise_price":1.09,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":39475},"source":{"system":"sec-edgar","filing":"0001683168-23-007106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823007106/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-25"}},{"id":1761205,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":45701,"kind":"person","name":"Charles Faith L.","position":1,"cik":"0001853985","reported_name":"Charles Faith L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-10-12T18:00:09.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":26315,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":29815,"derivative":{"exercise_price":1.09,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":26315},"source":{"system":"sec-edgar","filing":"0001683168-23-007107","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853985/000168316823007107/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-25"}},{"id":1773797,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":35682,"kind":"person","name":"Keyes Jeffry R.","position":1,"cik":"0001557736","reported_name":"Keyes Jeffry R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-09-25T22:27:21.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":68961,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":74914,"derivative":{"exercise_price":1.09,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":68961},"source":{"system":"sec-edgar","filing":"0001683168-23-006686","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557736/000168316823006686/ownership.xml","form_type":"4"}},{"id":1773749,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72876,"kind":"person","name":"Gumulka Jerzy","position":1,"cik":"0001793252","reported_name":"Gumulka Jerzy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-09-25T22:26:26.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":68961,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":74914,"derivative":{"exercise_price":1.09,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":68961},"source":{"system":"sec-edgar","filing":"0001683168-23-006684","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823006684/ownership.xml","form_type":"4"}},{"id":1773748,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":92076,"kind":"person","name":"Evans Carl Anthony","position":1,"cik":"0001792582","reported_name":"Evans Carl Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-09-25T22:24:59.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":68961,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":74914,"derivative":{"exercise_price":1.09,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":68961},"source":{"system":"sec-edgar","filing":"0001683168-23-006682","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823006682/ownership.xml","form_type":"4"}},{"id":1773747,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":38058,"kind":"person","name":"Cockroft Bettina M.","position":1,"cik":"0001900452","reported_name":"Cockroft Bettina M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-09-25T22:21:42.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":16551,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":74914,"derivative":{"exercise_price":1.09,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":18650},"source":{"system":"sec-edgar","filing":"0001683168-23-006680","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823006680/ownership.xml","form_type":"4"}},{"id":1773746,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":109030,"kind":"person","name":"Andraczke Andrzej","position":1,"cik":"0001792732","reported_name":"Andraczke Andrzej","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-09-25T22:20:12.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":68961,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":74914,"derivative":{"exercise_price":1.09,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":68961},"source":{"system":"sec-edgar","filing":"0001683168-23-006676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823006676/ownership.xml","form_type":"4"}},{"id":1774021,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":45701,"kind":"person","name":"Charles Faith L.","position":1,"cik":"0001853985","reported_name":"Charles Faith L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-09-25T18:20:56.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":45974,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":74914,"derivative":{"exercise_price":1.09,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":49474},"source":{"system":"sec-edgar","filing":"0001683168-23-006678","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853985/000168316823006678/ownership.xml","form_type":"4"}},{"id":1798721,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-23T12:00:04.000Z","date":"2023-08-22","kind":"purchase","planned":false,"acquired":true,"shares":27000,"price":1.2658,"value":34176.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.2196 to $1.2999. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":36772,"source":{"system":"sec-edgar","filing":"0001683168-23-006001","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316823006001/ownership.xml","form_type":"4"}},{"id":1805758,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-16T16:01:05.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":2750,"price":1.798,"value":4944.5,"ownership":{"direct":true},"balance_after":49010,"source":{"system":"sec-edgar","filing":"0001683168-23-005828","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316823005828/ownership.xml","form_type":"4"}},{"id":1810596,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":38058,"kind":"person","name":"Cockroft Bettina M.","position":1,"cik":"0001900452","reported_name":"Cockroft Bettina M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-08-11T01:14:44.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":2099,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options set forth in this table vest in 36 equal monthly installments succeeding the issuance date, or May 5, 2023, subject to the grantee's continued service on the Company's Board of Directors on each vesting date."}],"balance_after":2099,"derivative":{"exercise_price":1.67,"expiration_date":"2033-05-05","underlying":"Common Stock","underlying_shares":2099},"source":{"system":"sec-edgar","filing":"0001683168-23-005536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823005536/ownership.xml","form_type":"4/A","original_submission_date":"2023-05-09"}},{"id":1818917,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-28","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":1.04,"value":10400.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":156807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818916,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-27","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":1.09,"value":5450.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":166807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818915,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-24","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":1.08,"value":5400.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":171807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818914,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-23","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":1.08,"value":10800.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":176807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818913,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-22","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":1.08,"value":5400.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":186807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818912,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-21","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":1.1,"value":5500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":191807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818911,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-20","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":1.08,"value":5400.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":196807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818910,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-17","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":1.13,"value":5650.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":201807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818909,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-16","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":1.24,"value":6200.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":206807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818908,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-15","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":1.22,"value":6100.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":211807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818907,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-14","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":1.35,"value":6750.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":216807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818906,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-13","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":1.3,"value":6500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":221807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818905,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2023-03-10","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":1.29,"value":6450.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":226807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818904,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2022-12-09","kind":"sale","planned":true,"acquired":false,"shares":2798,"price":2.43,"value":6799.14,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":231807,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818903,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2022-12-08","kind":"sale","planned":true,"acquired":false,"shares":5500,"price":2.4,"value":13200.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":234605,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818902,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2022-12-07","kind":"sale","planned":true,"acquired":false,"shares":5500,"price":2.46,"value":13530.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":240105,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1818901,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-08-01T17:10:16.000Z","date":"2022-12-06","kind":"sale","planned":true,"acquired":false,"shares":5500,"price":2.47,"value":13585.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc."}],"balance_after":245605,"source":{"system":"sec-edgar","filing":"0000897069-23-001044","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000089706923001044/form4.xml","form_type":"4"}},{"id":1899111,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":38058,"kind":"person","name":"Cockroft Bettina M.","position":1,"cik":"0001900452","reported_name":"Cockroft Bettina M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-05-09T21:11:08.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":8300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options set forth in this table vest in 36 equal monthly installments succeeding the issuance date, or May 5, 2023, subject to the grantee's\ncontinued service on the Company's Board of Directors on each vesting date."}],"balance_after":8300,"derivative":{"exercise_price":1.67,"expiration_date":"2023-05-05","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001683168-23-003078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823003078/ownership.xml","form_type":"4"}},{"id":1910198,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-05-01T22:59:47.000Z","date":"2023-04-28","kind":"exercise","planned":false,"acquired":false,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 28, 2022, the reporting person received 8,335 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On April 28, 2022, the reporting person received 8,335 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On April 28, 2022, the reporting person received 8,335 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."}],"balance_after":28248,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001683168-23-002829","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316823002829/ownership.xml","form_type":"4"}},{"id":1910197,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-01T22:59:47.000Z","date":"2023-04-28","kind":"exercise","planned":false,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":9772,"source":{"system":"sec-edgar","filing":"0001683168-23-002829","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316823002829/ownership.xml","form_type":"4"}},{"id":1910124,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-05-01T18:59:57.000Z","date":"2023-04-28","kind":"exercise","planned":false,"acquired":false,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."}],"balance_after":60201,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001683168-23-002830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316823002830/ownership.xml","form_type":"4"}},{"id":1910123,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-01T18:59:57.000Z","date":"2023-04-28","kind":"exercise","planned":false,"acquired":true,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":46260,"source":{"system":"sec-edgar","filing":"0001683168-23-002830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316823002830/ownership.xml","form_type":"4"}},{"id":1915446,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72876,"kind":"person","name":"Gumulka Jerzy","position":1,"cik":"0001793252","reported_name":"Gumulka Jerzy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-21T11:58:55.000Z","date":"2023-04-19","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":1.7,"value":4250.0,"ownership":{"direct":true},"balance_after":9673,"source":{"system":"sec-edgar","filing":"0001683168-23-002562","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823002562/ownership.xml","form_type":"4"}},{"id":1918130,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-04-18T12:00:05.000Z","date":"2023-04-17","kind":"purchase","planned":false,"acquired":true,"shares":3100,"price":3.2,"value":9920.0,"ownership":{"direct":true},"balance_after":9251,"source":{"system":"sec-edgar","filing":"0001683168-23-002495","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316823002495/ownership.xml","form_type":"4"}},{"id":1918815,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72876,"kind":"person","name":"Gumulka Jerzy","position":1,"cik":"0001793252","reported_name":"Gumulka Jerzy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-17T12:17:37.000Z","date":"2023-04-10","kind":"purchase","planned":false,"acquired":true,"shares":7173,"price":0.74,"value":5308.02,"ownership":{"direct":true},"balance_after":7173,"source":{"system":"sec-edgar","filing":"0001683168-23-002424","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823002424/ownership.xml","form_type":"4"}},{"id":1919563,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-14T16:20:05.000Z","date":"2023-04-12","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.6939,"value":10408.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.677 to $0.70. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":45010,"source":{"system":"sec-edgar","filing":"0001683168-23-002405","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316823002405/ownership.xml","form_type":"4"}},{"id":1934020,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-31T23:28:10.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":6067,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events)."}],"balance_after":28768,"derivative":{"underlying":"Common stock","underlying_shares":6067},"source":{"system":"sec-edgar","filing":"0001683168-23-002095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316823002095/ownership.xml","form_type":"4"}},{"id":1933927,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-31T19:28:42.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":16467,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events)."}],"balance_after":61451,"derivative":{"underlying":"Common stock","underlying_shares":16467},"source":{"system":"sec-edgar","filing":"0001683168-23-002096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316823002096/ownership.xml","form_type":"4"}},{"id":2068439,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":45701,"kind":"person","name":"Charles Faith L.","position":1,"cik":"0001853985","reported_name":"Charles Faith L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-01-04T16:02:23.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":3500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options set forth in this table vest in 36 equal monthly installments succeeding the issuance date, or December 30, 2022, subject to the grantee's continued service on the Company's Board of Directors on each vesting date."}],"balance_after":3500,"derivative":{"exercise_price":2.4,"expiration_date":"2022-12-30","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001683168-23-000026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853985/000168316823000026/ownership.xml","form_type":"4"}},{"id":2287936,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-04-29T21:12:32.000Z","date":"2022-04-28","kind":"grant","acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."}],"balance_after":681000,"derivative":{"underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001683168-22-003054","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316822003054/ownership.xml","form_type":"4"}},{"id":2287943,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-04-29T17:11:50.000Z","date":"2022-04-28","kind":"grant","acquired":true,"shares":600000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors."}],"balance_after":1349500,"derivative":{"underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001683168-22-003053","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316822003053/ownership.xml","form_type":"4"}},{"id":2335570,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-14T13:40:12.000Z","date":"2022-03-11","kind":"grant","acquired":true,"shares":33000,"price":0.31,"value":10230.0,"ownership":{"direct":true},"balance_after":184500,"source":{"system":"sec-edgar","filing":"0001683168-22-001631","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316822001631/ownership.xml","form_type":"4"}},{"id":2341167,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":35682,"kind":"person","name":"Keyes Jeffry R.","position":1,"cik":"0001557736","reported_name":"Keyes Jeffry R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-09T19:34:40.000Z","date":"2022-03-07","kind":"grant","acquired":true,"shares":11100,"price":0.2968,"value":3294.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.2685 to $2999. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":11100,"source":{"system":"sec-edgar","filing":"0001683168-22-001546","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557736/000168316822001546/ownership.xml","form_type":"4"}},{"id":2341008,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":92076,"kind":"person","name":"Evans Carl Anthony","position":1,"cik":"0001792582","reported_name":"Evans Carl Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-09T19:34:18.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":3750,"price":0.268,"value":1005.0,"ownership":{"direct":true},"balance_after":3750,"source":{"system":"sec-edgar","filing":"0001683168-22-001545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316822001545/ownership.xml","form_type":"4"}},{"id":2344413,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-08T08:30:22.000Z","date":"2022-03-07","kind":"grant","acquired":true,"shares":35000,"price":0.281,"value":9835.0,"ownership":{"direct":true},"balance_after":940298,"source":{"system":"sec-edgar","filing":"0001683168-22-001495","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316822001495/ownership.xml","form_type":"4"}},{"id":2426343,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":110982,"kind":"person","name":"Priebe Waldemar","position":1,"cik":"0001678516","reported_name":"Priebe Waldemar","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-25T16:05:13.000Z","date":"2020-05-05","kind":"other","acquired":false,"shares":1495867,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares are held by a limited liability company for which the reporting person's adult child is the sole manager and adult children are sole members. Prior to May 5, 2020, the reporting person was a manager of the limited liability company. The reporting person ceased to be a manager of the limited liability company on May 5, 2020, and since such date has not had any voting or dispositive power over the shares held by the limited liability company. The reporting person has never had a pecuniary interest in the limited liability company."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of: (i) 7,333,133 shares of common stock held by a limited liability company; and (ii) 200,000 shares held by Houston Pharmaceuticals, Inc."}],"balance_after":7533133,"source":{"system":"sec-edgar","filing":"0001683168-22-000460","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678516/000168316822000460/ownership.xml","form_type":"4"}},{"id":2482324,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-07T13:30:08.000Z","date":"2021-12-06","kind":"purchase","acquired":true,"shares":5000,"price":0.9403,"value":4701.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.9400 to $0.947299. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":151500,"source":{"system":"sec-edgar","filing":"0001683168-21-006141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316821006141/ownership.xml","form_type":"4"}},{"id":2500904,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":19585,"kind":"person","name":"Downs Christopher S","position":1,"cik":"0001705978","reported_name":"Downs Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-22T13:47:56.000Z","date":"2021-11-19","kind":"purchase","acquired":true,"shares":4500,"price":1.1537,"value":5191.65,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.14 to $1.155. The price reported above reflects the weighted average purchase\nprice. The reporting person hereby undertakes to provide upon upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of\nshares and prices at which the transaction was effected."}],"balance_after":146500,"source":{"system":"sec-edgar","filing":"0001683168-21-005869","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705978/000168316821005869/ownership.xml","form_type":"4"}},{"id":2504773,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72888,"kind":"person","name":"Climaco John M","position":1,"cik":"0001546797","reported_name":"Climaco John M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-18T20:07:58.000Z","date":"2021-11-16","kind":"grant","acquired":true,"shares":5000,"price":1.28,"value":6400.0,"ownership":{"direct":true},"balance_after":905298,"source":{"system":"sec-edgar","filing":"0001683168-21-005823","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1546797/000168316821005823/ownership.xml","form_type":"4"}},{"id":2631565,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":109030,"kind":"person","name":"Andraczke Andrzej","position":1,"cik":"0001792732","reported_name":"Andraczke Andrzej","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2021-07-16T21:00:40.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":32000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date hereof or the date of the 2022 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":178559,"derivative":{"exercise_price":1.8,"expiration_date":"2031-07-15","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001683168-21-002999","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316821002999/ownership.xml","form_type":"4"}},{"id":2631564,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":72876,"kind":"person","name":"Gumulka Jerzy","position":1,"cik":"0001793252","reported_name":"Gumulka Jerzy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2021-07-16T21:00:33.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":32000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued in connection with the reporting person's Board of Director services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options set forth in this table vest on the earlier of the one-year anniversary of the date hereof or the date of the 2022 annual meeting, subject to the grantee's continued service to the Company on the vesting date."}],"balance_after":178559,"derivative":{"exercise_price":1.8,"expiration_date":"2031-07-15","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001683168-21-003000","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316821003000/ownership.xml","form_type":"4"}}],"next_cursor":"2021-07-16T21:00:33.000000Z,2631564"}